To Evaluate the Safety and Tolerability of SYHX2001 in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors Clinical Trial

Official title:

To Evaluate the Safety and Tolerability of SYHX2001 in Patients With Advanced or Metastatic Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05407909
• Other study ID #: SYHX2001C101
• Status: Recruiting
• Phase: Phase 1
• Start date: July 27, 2022
• Est. completion date: January 6, 2026

Study information

• Verified date: August 2022
• Source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Contact: Xiaodong Wang
• Phone: +86 021-60673947
• Email: wang_xiaodong[@]mail.ecspc.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, open-label, multicenter, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the experimental drug(SYHX2001) in previously treated patients with advanced or metastatic cancer.

Description:

This is a multicenter, open-label, dose-escalation, dose-expansion Phase 1 study of SYHX2001(name of the experimental drug) in patients with advanced or metastatic cancers who have exhausted standard treatment. The study will consist of 2 parts, a dose escalation part and a cohort expansion part. Once the recommended phase 2 dose (RP2D) has been determined in the dose escalation part, a cohort expansion part involving up to three separate cohorts will be conducted. For patients, the study will include a screening phase, a treatment phase, and a post treatment follow-up phase. An end-of-study visit will be conducted within 30 days after the last dose of SYHX2001.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 176
• Est. completion date: January 6, 2026
• Est. primary completion date: January 6, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Male or female patients with an age of 18~75years (inclusive).

2. Confirmed histologic or cytologic diagnosis of an advanced and/or metastatic solid tumor.

3. At least one measurable lesion as defined by RECIST version 1.1.

4. Eastern Cooperative Oncology Group Performance Status 0 or 1.

5. Life expectancy =3 months.

6. Major organ function within 14 days prior to treatment meets the following criteria (no blood transfusion, Erythropoietin(EPO), Granulocyte Colony Stimulating Factor(G-CSF) or other medical support): Absolute Neutrophil Count(ANC)=1.5×10^9/L,Platelet(PLT)=90×10^9/L,Hemoglobin(Hb)=100g/L or=6.2 mmol/L;Creatinine(Cr)=1.5×upper limit of normal(ULN) and creatinine clearance rate=50mL/min;Total Bilirubin(TBIL)=1.5×ULN; Prothrombin time(PT)=1.5×ULN , Activated Partial Thromboplastin Time(APTT)=1.5×ULN , Aspartate Aminotransferase(AST)/Alanine Aminotransferase(ALT)=2.5 × ULN.

7. Signed informed consent form.

Exclusion Criteria:

1. Chemotherapy, radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy and other anti-tumor treatment within 4 weeks prior to the first dose of the study drug, or administration of other investigational agents within 4 weeks or 5 half-lives prior to the first dose of the study drug, whichever is longer.

2. Major surgery or significant trauma within 4 weeks prior to the first dose of the study drug.

3. Adverse reactions from the previous anti-tumor treatment have not yet recovered to = level 1 based on CTCAE 5.0?

4. Have a history of severe cardiovascular and cerebrovascular disease.

5. Central nervous system metastasis or meningeal metastasis with clinical symptoms, or other evidence shows that the patient's central nervous system metastasis or meningeal metastasis has not been controlled and not suitable for the study according to the judgment of the investigator.

6. Known history of hypersensitivity to test drug components.

7. Patients with recent active bleeding or a history of bleeding.

8. Those with coagulation disorders or taking thrombolytic, anticoagulant or antiplatelet agglutination drugs.

9. Gastrointestinal perforation, abdominal fistula, or intra-abdominal abscess within 6 months prior to first dose; or currently under investigator's judgement there are high risk factors for hollow organ perforation/fistula formation).

10. Inability to swallow the drug orally, or a condition that seriously affects gastrointestinal absorption in the judgment of the investigator.

11. Irritable bowel syndrome with signs/symptoms requiring medication.

12. Persistent active diarrhea requiring medical treatment.

13. Concomitant use of strong CYP3A4 inhibitors or inducers, strong CYP2D6 inhibitors and strong P-gp inhibitors within 14 days prior to the first dose of the study drug.

14. History of autoimmune diseases, immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency, or organ transplant history.

15. Known Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or other active viral infection.

16. Male and female patients of childbearing potential do not agree to use suitable method of contraception during the treatment and 6 months after the last dose of study medication; female patients do not have negative results of serum/urine pregnancy test within 7 days prior to enrollment and would be breastfeeding.

17. Not suitable for this study as determined by the investigator due to other reasons.

Related Conditions & MeSH terms

• Advanced or Metastatic Solid Tumors
• Neoplasms

Intervention

Drug:
• SYHX2001
SYHX2001 tablets, oral

Locations

Country	Name	City	State
China	Harbin Medical University Cancer Hospital	Harbin	Heilongjiang

Sponsors (1)

Lead Sponsor	Collaborator
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose limiting toxicities (DLT) in stage ?		Baseline through Day 28
Primary	Maximum tolerated dose (MTD) in stage ?		Baseline through Day 28
Primary	Recommended phase 2 dose (RP2D)		Baseline through approximately 2 years
Primary	Incidence and severity of adverse events in stage ?		Baseline through approximately 2 years
Primary	Overall response rate (ORR) in stage ?		Up to approximately 2 years
Secondary	Maximum observed plasma concentration (Cmax) of SYHX2001		Baseline and up to approximately 2 years
Secondary	Area under the plasma concentration-time curve (AUC) extrapolated from time zero to infinity (AUC[0-inf]) of SYHX2001		up to approximately 2 years
Secondary	AUC from time zero to the last quantifiable concentration after dosing (AUC[0-t]) of SYHX2001		up to approximately 2 years
Secondary	Terminal phase half-life (t1/2) of SYHX2001		up to approximately 2 years
Secondary	Oral clearance (CL/F) of SYHX2001		up to approximately 2 years
Secondary	PFS Progression-free survival (PFS)	PFS is defined as the time from first dose until radiographic progression per standard criteria or death due to any cause, whichever is earlier.	up to approximately 2 years
Secondary	Duration of Response (DOR)	DOR is defined as the time from first evidence of response (complete response or partial response per RECIST 1.1) to earlier date of disease progression or death due to any cause.	up to approximately 2 years
Secondary	Number of patients with any adverse events(AEs) and serious adverse events(SAEs) in stage ?		up to approximately 2 years
Secondary	Change from Baseline in symmetrical arginine dimethylation (SDMA) as a pharmacodynamics(PD) measure		Baseline and up to approximately 2 years